Author

Leanne M Ward

Professor of Pediatrics, Children's Hospital of Eastern Ontario, University of Ottawa - Cited by 15,944 - Pediatric bone health - Endocrinology - Vitamin D - Bone dysplasias - Osteoporosis

Biography

Leanne M. Ward, MD is a Professor of Pediatrics at the University of Ottawa, where she has held a Research Chair in Pediatric Bone Health since 2010. She is the Scientific Director of the Ottawa Pediatric Bone Health Research Group, the Medical Director of the Genetic and Metabolic Bone Disease Clinic at the Children’s Hospital of Eastern Ontario (CHEO), and a pediatric endocrinologist in the Division of Endocrinology and Metabolism at CHEO.
Title
Cited by
Year
Bone mineral density surveillance for childhood, adolescent, and young adult cancer survivors: evidence-based recommendations from the International Late Effects of Childhood …
JE van Atteveld, RL Mulder, MM van den Heuvel-Eibrink, MM Hudson, ...The lancet Diabetes & endocrinology 9 (9), 622-637, 2021202
23
2021
Efficacy and safety of vamorolone in Duchenne muscular dystrophy: a 30-month nonrandomized controlled open-label extension trial
JK Mah, PR Clemens, M Guglieri, EC Smith, RS Finkel, M Tulinius, ...JAMA network open 5 (1), e44178-e44178, 2022202
21
2022
Effect of burosumab compared with conventional therapy on younger vs older children with X-linked hypophosphatemia
LM Ward, FH Glorieux, MP Whyte, CF Munns, AA Portale, W Högler, ...The Journal of Clinical Endocrinology & Metabolism 107 (8), e3241-e3253, 222
20
2022
Efficacy and safety of vamorolone vs placebo and prednisone among boys with Duchenne muscular dystrophy: a randomized clinical trial
M Guglieri, PR Clemens, SJ Perlman, EC Smith, I Horrocks, RS Finkel, ...JAMA neurology 79 (10), 1005-1014, 2022202
17
2022
Zoledronic acid vs placebo in pediatric glucocorticoid-induced osteoporosis: a randomized, double-blind, phase 3 trial
LM Ward, A Choudhury, N Alos, DA Cabral, C Rodd, AM Sbrocchi, ...The Journal of Clinical Endocrinology & Metabolism 106 (12), e5222-e5235, 2021202
14
2021
Musculoskeletal features in adults with X-linked hypophosphatemia: an analysis of clinical trial and survey data
MK Javaid, L Ward, R Pinedo-Villanueva, AJ Rylands, A Williams, ...The Journal of Clinical Endocrinology & Metabolism 107 (3), e49-e62, 2022202
12
2022
Vitamin D supplementation for children with cancer: A systematic review and consensus recommendations
JE van Atteveld, IE Verhagen, MM van den Heuvel‐Eibrink, ...Cancer Medicine 10 (13), 4177-4194, 2021202
11
2021
An international comparative analysis of public reimbursement of orphan drugs in Canadian provinces compared to European countries
LM Ward, A Chambers, E Mechichi, D Wong-Rieger, C CampbellOrphanet Journal of Rare Diseases 17 (1), 1-14, 2022202
8
2022
Osteoporotic fractures and vertebral body reshaping in children with glucocorticoid-treated rheumatic disorders
LM Ward, J Ma, ME Robinson, M Scharke, J Ho, K Houghton, A Huber, ...The Journal of Clinical Endocrinology & Metabolism 10 (12), e5195-e5207, 2021202
6
2021
Dominant osteogenesis imperfecta with low bone turnover caused by a heterozygous SP7 variant
K Ludwig, LM Ward, N Khan, ME Robinson, V Miranda, G Bardai, ...Bone 10, 11400, 2022202
6
2022
A validated risk prediction model for bone fragility in children with acute lymphoblastic leukemia
EJ Verwaaijen, J Ma, HA de Groot‐Kruseman, R Pieters, IM Van Der Sluis, ...Journal of Bone and Mineral Research 36 (12), 2290-2299, 2021202
4
2021
Vamorolone versus corticosteroid real-world experience: Comparisons of 2-year treatment period with NorthStar UK Network and CINRG Duchenne Natural History Study
J Mah, P Clemens, M Guglieri, E Smith, R Finkel, M Tulinius, Y Nevo, ...NEUROMUSCULAR DISORDERS 1, 2021202
3
2021
CLINICAL TRIAL HIGHLIGHTS: O. 3a 2.5-years of vamorolone treatment in Duchenne muscular dystrophy: Results of an open label long-term extension
CLINICAL TRIAL HIGHLIGHTS: O. a 2.5-years of vamorolone treatment in Duchenne muscular dystrophy: Results of an open label long-term extensionE Hoffman, U Dang, P Clemens, H Gordish-Dressman, B Schwartz, ...Neuromuscular Disorders 1, S48, 2021202
3
2021
DMD-TREATMENT: EP. 147 2.5-years of vamorolone treatment in Duchenne muscular dystrophy: Results of an open label long-term extension
E Hoffman, U Dang, P Clemens, H Gordish-Dressman, B Schwartz, ...Neuromuscular Disorders 1, S9-S94, 2021202
3
2021
La prévention de la carence en vitamine D symptomatique et du rachitisme chez les nourrissons et les enfants autochtones du Canada
J Irvine, LM WardPaediatrics & Child Health 7 (), 18-18, 0
2
2022
The Effects of Physical Activity on Physeal and Skeletal Development
S Carsen, G Grammatopoulos, I Zaltz, L Ward, K Smit, PE BeauléJBJS reviews 9 (10), e1, 010
2
2021
Sickle cell bone disease and response to intravenous bisphosphonates in children
C Grimbly, PD Escagedo, JL Jaremko, A Bruce, N Alos, ME Robinson, ...Osteoporosis International 33 (), 2397-2408, 2022202
1
2022
RANKL Inhibition Reduces Cardiac Hypertrophy in mdx Mice and Possibly in Children with Duchenne Muscular Dystrophy
L Marcadet, ES Juracic, N Khan, Z Bouredji, H Yagita, LM Ward, ...Cells 2 (), 538, 2023202
1
2023

Referred From: https://scholar.google.com/citations?user=CrklymAAAAAJ&hl=en

Cited by
Citations 15944
h-index 55
i10-index 108
Open Access Journals